Delaware Court Heard Arguments on Vividion Sale Price
Investors are challenging the $2 billion acquisition price, claiming intellectual property valuation concerns.
Updated on Sept. 23, 2026 in Healthcare
Live Poll
Do you trust that courts effectively ensure fair pricing in large corporate acquisitions?
The Delaware Supreme Court heard oral arguments regarding the $2 billion acquisition of Vividion Therapeutics by Bayer AG. Investors contend that the final sale price was undervalued due to issues surrounding specific patent control.
Why it matters
This case highlights the risks for operators and investors when intellectual property ownership becomes a central point of contention during a corporate acquisition. It underscores how disputes over specific assets can lead to significant litigation long after a deal closes.
The case, numbered 70,2026, centers on the $2 billion acquisition price paid by Bayer AG for Vividion Therapeutics. It remains unresolved whether the valuation properly reflected all intellectual property assets.
The players
Bayer AG
A multinational pharmaceutical and life sciences company focused on research and development in healthcare and agriculture.
Vividion Therapeutics
A biotechnology company focused on drug discovery that was acquired to bolster a larger pharmaceutical portfolio.
Cardinal Partners
An investment firm that challenged the acquisition valuation of a portfolio company.
Delaware Supreme Court
The highest state court in Delaware which plays a critical role in adjudicating corporate governance and acquisition disputes.
The details
The court conducted an oral argument session in CHP III LP v. Cravatt to examine claims that Bayer AG would have paid a higher premium if the target company held control of a specific patent. Cardinal Partners argues that the valuation of the acquisition was insufficient, suggesting that the deal terms did not adequately capture the full value of the intellectual property portfolio that Bayer AG sought to obtain.
Timeline
September 23, 2026: The Delaware Supreme Court heard oral arguments.
Market Landscape
This litigation follows long-standing patterns in Delaware where courts review whether acquisition prices reflect the fair value of all underlying assets. The dispute highlights the ongoing tension between buyer-offered premiums and investor expectations regarding undisclosed intellectual property value.
Business owners should ensure all intellectual property rights are clearly documented before any acquisition negotiation begins. Misalignment on patent control can lead to lengthy post-merger litigation that consumes significant resources and management time.
The takeaway
Operational value often hinges on the clarity and transferability of specific intellectual property assets during an exit. Operators should audit their patent portfolios and ownership documentation regularly to prevent valuation disputes in future exit scenarios.
Further reading
For more on industry shifts, see Healthcare.
Source note: This article includes information reported by Bloomberglaw.
Live Poll
Do you trust that courts effectively ensure fair pricing in large corporate acquisitions?
